Meng Fang, Kwok Maxwell, Hui Yen Chin, Wei Ruofan, Hidalgo-Gonzalez Alejandro, Walentinsson Anna, Andersson Henrik, Bjerre Frederik Adam, Wang Qing-Dong, Andersen Ditte C, Poon Ellen Ngar-Yun, Später Daniela, Zebrowski David C
Department of Biology, New York University, New York, NY, USA.
Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, The People's Republic of China.
J Mol Cell Cardiol Plus. 2025 Mar 28;12:100295. doi: 10.1016/j.jmccpl.2025.100295. eCollection 2025 Jun.
Human induced Pluripotent Stem Cell-derived cardiomyocytes (hiPSC-CMs) are increasingly used to identify potential factors capable of inducing endogenous cardiomyocyte proliferation to regenerate the injured heart. L-type calcium channel blockers have previously been identified as a class of factors capable of inducing matured hiPSC-CMs to proliferate. However, the mechanism by which L-type calcium channel blockers promote hiPSC-CM proliferation remains unclear. Here we provide evidence that matured hiPSC-CMs possess plasticity to undergo dematuration in response to certain pharmacological compounds. Consistent with primary cardiomyocyte maturation during perinatal development, we found that centrosome disassembly occurs in hiPSC-CMs during plate-based, temporal, maturation. A small molecule screen identified nitrendipine, an L-type calcium channel blocker, and 1-NA-PP1, a Src kinase inhibitor, as factors capable of inducing centrosome reassembly in a subpopulation of hiPSC-CMs. Furthermore, centrosome-positive hiPSC-CMs were more likely to exhibit cell cycle activity than centrosome-negative hiPSC-CMs. In contrast, neither nitrendipine or 1-NA-PP1 induced centrosome reassembly, or cell cycle activity, in neonatal rat ventricular myocytes (NRVMs). Differential bulk transcriptome analysis indicated that matured hiPSC-CMs, but not NRVMs, treated with nitrendipine or 1-NA-PP1 undergo dematuration. ScRNA transcriptome analysis supported that matured hiPSC-CMs treated with either nitrendipine or 1-NA-PP1 undergo dematuration. Collectively, our results indicate that matured hiPSC-CMs, but not primary NRVMs, possess plasticity to undergo dematuration in response to certain pharmacological compounds such as L-type calcium channel blockers and Src-kinase inhibitors. This study shows that once mature, hiPSC-CMs may not maintain their maturity under experimental conditions which may have implications for experimental systems where the state of hiPSC-CM maturation is relevant.
人诱导多能干细胞衍生的心肌细胞(hiPSC-CMs)越来越多地用于鉴定能够诱导内源性心肌细胞增殖以再生受损心脏的潜在因子。L型钙通道阻滞剂此前已被确定为一类能够诱导成熟hiPSC-CMs增殖的因子。然而,L型钙通道阻滞剂促进hiPSC-CM增殖的机制仍不清楚。在此,我们提供证据表明,成熟的hiPSC-CMs具有可塑性,能够响应某些药理化合物而发生去分化。与围产期发育过程中的原代心肌细胞成熟一致,我们发现基于平板的、时间性的成熟过程中,hiPSC-CMs会发生中心体解体。小分子筛选确定了L型钙通道阻滞剂尼群地平和Src激酶抑制剂1-NA-PP1是能够在一部分hiPSC-CMs中诱导中心体重组的因子。此外,中心体阳性的hiPSC-CMs比中心体阴性的hiPSC-CMs更有可能表现出细胞周期活性。相比之下,尼群地平和1-NA-PP1均未在新生大鼠心室肌细胞(NRVMs)中诱导中心体重组或细胞周期活性。差异整体转录组分析表明,用尼群地平或1-NA-PP1处理的成熟hiPSC-CMs会发生去分化,而NRVMs则不会。单细胞RNA转录组分析支持用尼群地平或1-NA-PP1处理的成熟hiPSC-CMs会发生去分化。总体而言,我们的结果表明,成熟的hiPSC-CMs而非原代NRVMs具有可塑性,能够响应某些药理化合物(如L型钙通道阻滞剂和Src激酶抑制剂)而发生去分化。这项研究表明,hiPSC-CMs一旦成熟,在实验条件下可能无法维持其成熟状态,这可能对hiPSC-CM成熟状态相关的实验系统产生影响。